The Hidden Winner of the FDA’s Anti-Generic Decision

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

In this video, Motley Fool health-care analyst David Williamson discusses the hidden winner of today's big FDA decision not to approve generic OxyContin despite a patent running out this week.

Big Pharma Pfizer sells an abuse-resistant, instant-acting version that will now avoid generic competition, but the hidden winner is the company whose technology makes the drug possible -- Acura Pharmaceuticals. This small cap popped more than 50% intraday, before settling with a 33% gain. Watch and find out what this means for investors.

What macro trend was Warren Buffett referring to when he said, "This is the tapeworm that's eating at American competitiveness"? Find out in our free report: What's Really Eating at America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 17, 2013, at 9:02 PM, shortsrscrewed wrote:

    No one has even mentioned the fact the new patent may create problems for existing manufacturers. In addition, once the major investment houses realize the extent of ACUR's patents coverage, current products and pipeline products the upside on this stock is unlimited!

    If the shorts get squeezed on this, the stock could be north of 6 in a heartbeat.....

    Very long on this stock and I think it will prove out in the long term.

  • Report this Comment On April 18, 2013, at 11:59 AM, Retaility wrote:

    Any input as to why ACUR is in the toilet after it was announced that the big 3 are going to distribute nexafed to retail pharmacies? That would seem like good news, after all. There was a pop when it was sold at a tiny chain that no one has ever heard of. This stock stinks of manipulation

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2369578, ~/Articles/ArticleHandler.aspx, 9/25/2016 1:59:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
ACUR $1.66 Down -0.01 -0.60%
Acura Pharmaceutic… CAPS Rating: ***
PFE $34.26 Up +0.11 +0.32%
Pfizer CAPS Rating: ****
PTIE $2.73 Down -0.13 -4.55%
Pain Therapeutics CAPS Rating: ***